California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
(4) - EconoTimes)
CHESTERBROOK, Pa., Aug. 14, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of July 31, August 7, and August 10, 2017, the grant of inducement stock options to purchase an aggregate of 87,000 shares of the Company’s common stock to four new employees. These awards were granted pursuant to the Trevena, Inc. Inducement Plan as an inducement material to the new employees entering into employment with the Company, in accordance with NASDAQ Listing Rule 5635(c)(4).
The first stock option grant, for 27,000 shares, has an exercise price per share of $2.61, the closing stock price on July 31, 2017. The second and third stock option grants, both for 20,000 shares, have an exercise price per share of $2.48, the closing stock price on August 7, 2017. The fourth stock option, for 20,000 shares, has an exercise price per share of $2.34, the closing stock price on August 10, 2017. Each option grant has a ten-year term and will vest with respect to one-fourth of the total number of shares subject to the option on each of first, second, third, and fourth anniversaries of the grant date.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO. Trevena also has discovered TRV250, in early clinical development for the treatment of migraine, and TRV734 for pain. The Company maintains an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Vice President, Corporate Strategy & Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
